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Abstract
Background: Metabolic syndrome (MetS) and body mass index (BMI, kg.m
-2) are established independent risk
factors in the development of diabetes; we prospectively examined their relative contributions and joint
relationship with incident diabetes in a Middle Eastern cohort.
Method: participants of the ongoing Tehran lipid and glucose study are followed on a triennial basis. Among non-
diabetic participants aged≥ 20 years at baseline (8,121) those with at least one follow-up examination (5,250) were
included for the current study. Multivariate logistic regression models were used to estimate sex-specific adjusted
odd ratios (ORs) and 95% confidence intervals (CIs) of baseline BMI-MetS categories (normal weight without MetS
as reference group) for incident diabetes among 2186 men and 3064 women, aged ≥ 20 years, free of diabetes at
baseline.
Result: During follow up (median 6.5 years); there were 369 incident diabetes (147 in men). In women without
MetS, the multivariate adjusted ORs (95% CIs) for overweight (BMI 25-30 kg/m2) and obese (BMI≥30) participants
were 2.3 (1.2-4.3) and 2.2 (1.0-4.7), respectively. The corresponding ORs for men without MetS were 1.6 (0.9-2.9) and
3.6 (1.5-8.4) respectively. As compared to the normal-weight/without MetS, normal-weight women and men with
MetS, had a multivariate-adjusted ORs for incident diabetes of 8.8 (3.7-21.2) and 3.1 (1.3-7.0), respectively. The
corresponding ORs for overweight and obese women with MetS reached to 7.7 (4.0-14.9) and 12.6 (6.9-23.2) and
for men reached to 3.4(2.0-5.8) and 5.7(3.9-9.9), respectively.
Conclusion: This study highlights the importance of screening for MetS in normal weight individuals. Obesity
increases diabetes risk in the absence of MetS, underscores the need for more stringent criteria to define healthy
metabolic state among obese individuals. Weight reduction measures, thus, should be encouraged in conjunction
with achieving metabolic targets not addressed by current definition of MetS, both in every day encounter and
public health setting.
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Background
Diabetes is “a common, growing, serious, costly, and
potentially preventable public health problem” [1].
Metabolic syndrome (MetS) and body mass index (BMI)
are established independent risk factors in the develop-
ment of diabetes [2]. Obesity consists of heterogeneous
phenotypes resulting from interplay between genetic and
environmental factors [3]. Increased BMI has been asso-
ciated with metabolic and cardiovascular risk factors
including diabetes, hypertension, dyslipidemia, but there
is increasing evidence that sub-phenotypes of obesity
exist that appear to deviate from the standard dose-
response relationship between increased BMI and its
adverse clinical outcomes [4]. Metabolically obese but
normal-weight (normal-weight/MetS) is a condition to
be ascertained in individuals who despite having a nor-
mal-weight BMI, present metabolic disturbances typical
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as MetS, includes impaired insulin sensitivity, increased
visceral adiposity, low levels of high-density lipoprotein
cholesterol (HDL-C), elevated levels of fasting glucose
and triglycerides (TGs), and hypertension [5-9]. It has
been shown that the normal-weight/MetS phenotype is
associated with a three- to fourfold higher risk for dia-
betes as compared with control subjects [10]. On the
other hand, metabolically healthy but obese (obese/with-
out MetS) individuals, have been identified who, despite
having BMI exceeding 30 kg.m
-2, are relatively insulin
sensitive and have a rather favorable cardiovascular risk
profile [11-14] with a three- to fourfold lower risk for
diabetes as compared with obese insulin-resistant indivi-
duals [10]. There has been, however, no consensus
regarding the definitions of obese/without MetS [15-18]
and the existence of a healthy obese phenotype based
on the definition of absence of MetS [19] has recently
been questioned [20]. Since no population-based study
prospectively has examined sex-specifically the joint
relationship between BMI and MetS with diabetes [10],
an unanswered question remains to be whether the
impact of diagnosis of different obesity phenotype on
prediction of incident diabetes differs by sex.
Plethora of evidences currently supports the notion
that diabetes can be prevented or the onset delayed
[21,22]. In this light, the need for evidence-based guide-
lines for putting prevention into practice is seen as a
public health priority. It is, therefore, worthwhile to clar-
ify the combined effect of BMI and MetS for public
health systems in order to best support people by strati-
fying them by risk and in turn target those at highest
risk of developing diabetes in the future. Therefore,
using data based on a Middle Eastern population, we
investigated the combined relationship of BMI and
MetS with incident diabetes to understand if MetS mod-
ify increasing effect of BMI on diabetes.
Methods
Study population
The Tehran Lipid and Glucose Study (TLGS) is a pro-
spective population based study performed on a repre-
sentative sample of the Tehran population, with the
aim of determining the prevalence of non-communic-
able disease (NCD) risk factors and developing a
healthy lifestyle to improve them [11,12]. The baseline
survey was performed from February 1999 to July 2001
(phase 1) and 4751 families, which included more than
15,000 residents of district-13 of Tehran aged ≥3 years
were selected by cluster random-sampling method.
After this cross-sectional phase, subjects entered into a
cohort and a prospective interventional study (lifestyle
modification education). The current study used the
data from 10,368 individuals ≥ 20 years who had
baseline examination. After exclusion of participants
with prevalent diabetes (n = 1164), and those with
missing data regarding fasting and 2 hour post chal-
lenge plasma glucose (2 h-PCPG) (n = 884), BMI and
MetS definition (n = 199), 8,121 non-diabetic partici-
pants remained eligible to be reexamined in two con-
secutive phases, one from September 2001 to August
2005 (phase 2) and the other from April 2005 to
March 2008 (phase3). The same standard approach is
followed to collect information across consecutive
examinations of the TLGS follow up study. Partici-
pants with at least one follow-up examination (5,250)
were included for the current study (Figure 1).
Informed written consent was obtained from all parti-
cipants and the ethical committee of the Research Insti-
tute for Endocrine Sciences approved this study.
Clinical and laboratory measurements
A trained interviewer collected information using a pre-
tested questionnaire. The information obtained included
demographic data, family history of diabetes and past
medical history of cardiovascular disorder (CVD), drug
use and smoking behavior. Weight was measured, with
subjects minimally clothed without shoes, using digital
scales (Seca 707: range 0.1-150 kg) and recorded to the
nearest 100 g. Height was measured in a standing posi-
tion without shoes, using tape meter while shoulders
were in a normal alignment. Waist circumference (WC)
was measured at the umbilical level. Two measurements
of systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were taken using a standardized mercury
sphygmomanometer on the right arm, after a 15 minute
189 diabetics in phase2
4530 non-diabetics in phase2
3,402 not attending phase 2
714 Lost to Follow-up  2157 Lost to Follow-up
15,005 aged 3 years in phase1
10,368 aged 20years in phase1
1,164 diabetics in phase1 1,083 missing value 
8,121 total population in phase1
In phase2
In phase3
109 diabetics in phase3
3707 non-diabetics in phase3
71 diabetics in phase3
1174 non-diabetics in phase3
Figure 1 Study population, inclusions and exclusions.
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was considered as the subject’s blood pressure [12].
Fasting plasma glucose (FPG), serum HDL-C, and TGs
levels were measured by previously reported methods
[23,24]. BMI was calculated as weight (kg) divided by
square of the height (m
2).
Definition of terms
The normal-weight/MetS phenotype was defined as the
status of having normal weight (BMI < 25 kg.m
-2)b u t
meeting the MetS criteria. In contrast, obese/without
MetS phenotype was defined as the status of being
obese or overweight (BMI ≥ 25 kg.m
-2), but not having
MetS [18]. We used the updated harmonized definition
of MetS [25,26]. We used WC cutoff points known to
be appropriate for Persian men and women [27]. MetS
was ascertained in individuals meeting three or more of
the following criteria. (1) Waist circumference ≥ 94.5
cm. (2) HDL-C <1.04 mmol.l
-1 (40 mg.dl
-1) in men and
<1.30 mmol.l
-1 (50 mg.dl
-1)i nw o m e n .( 3 )T G s≥1.7
mmol.l
-1 (150 mg.dl
-1) or specific treatment for this lipid
abnormality. (4) Hypertension defined as SBP ≥130
mmHg or DBP ≥85 mmHg or treatment of previously
diagnosed hypertension. (5) fasting glucose ≥5.5 mmol.l
-
1 (100 mg.dl
-1) or previously diagnosed diabetes [28].
Smoking status included a record of current, occasional
and past smoking history (those who had never smoked
were called non-smokers). Positive family history of dia-
betes was defined as having at least one parent or sib-
ling with diabetes. Participants were classified as having
diabetes at the baseline or during follow-up if they met
at least one of these criteria: FPG ≥7 mmol.l
-1,o r2h -
PCPG≥11.1 mmol.l
-1 or taking anti-diabetic medication
[29]. A previous history of CVD reflected any prior diag-
nosis of CVD by a physician.
Statistics
To investigate the sex-specific combined effect of BMI
and MetS on the development of diabetes, joint BMI-
MetS variable was created. That is, participants were
divided into groups based on both their BMI (kg.m
-2)
(normal weight, <25, overweight 25-30, and obese ≥
30) [30] and MetS status [26]. Mean (SDs) were calcu-
lated for all continuous variables and the percentage of
participants in each BMI-MetS category was deter-
mined for all categorical variables. Values for TGs
levels were log-transformed since the distribution was
highly skewed. Differences among BMI-MetS cate-
gories were examined by Chi-square or ANOVA where
appropriate. The cumulative incidence of diabetes was
calculated as the number of diabetes events divided by
the number of subjects at risk in each category of
BMI-MetS. The independent and combined effects on
diabetes of both BMI and MetS were examined using
multivariable logistic regression models separately for
each sex. We chose our candidate covariates among
the ones that were validated from the literature and
new ones that are suspected of playing important roles
in the development of diabetes [31,32]. As such, our
covariate selection can be regarded as being guided by
scientific as well as numeric evidence. The following
variables served as standard candidate risk factors: age,
sex, body mass index (BMI), waist circumference, exer-
cise, diabetes, SBP, DBP, smoking, family history of
diabetes, TGs, and HDL-C [31]. We followed statistical
guidelines with respect to the significance of associa-
tion of a variable with incident diabetes but also con-
sidered scientific and qualitative judgment as well. For
example we did not adjusted for waist circumference,
TGs, HDL-C, and FPG which are components of the
MetS and therefore not appropriate to be adjusted for
in prediction models already incorporating MetS. Sex-
specific odds ratios (ORs) and their 95% confidence
intervals (CIs) were calculated using age- and multi-
variate-adjusted models, which included age, family
history of diabetes, history of cardiovascular disease
(CVD), education, smoking and the TLGS interven-
tions. Age- and multivariate-adjusted logistic regres-
sion models incorporating the joint variable were also
created. The normal weight individuals, without MetS
were the referent group when the combined effect of
the MetS and BMI were to be evaluated. When BMI
was the predictor under evaluation, the reference
group was normal weight individuals, regardless of
MetS status. When MetS was the predictor under eva-
luation, the participants without MetS were considered
as reference group. Hosmer-Lemeshow test for good-
ness-of-fit was implemented to assess the calibration of
logistic models [33]. Linearity in the regression coeffi-
cients of the continuous covariates were analyzed by
using multivariate restricted cubic splines [34].
Alternate analyses using Cox proportional hazards
models that accounted for interval censoring gave the
same results hence, only logistic regression results are
presented. Wald tests of the linear hypotheses concern-
ing the logistic regression models coefficients were per-
formed to test the null hypotheses that the ORs (effect
size) for one MetS-BMI category was equal to that of
another category. All statistical analyses were performed
using STATA version 10.0 (StataCorp LP, College Sta-
tion, Texas) and values of P < 0.05 from 2-sided tests
were considered statistically significant.
Results
Non-diabetic participants who did not attend the follow
up study have been considered as non-participants. At
baseline, as compared to non-participants, participants
had higher BMI (26.8 vs. 26.4 kg.m-2), WC (88 vs. 87
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-1), and prevalence
of family history of diabetes (26% vs. 24%). The preva-
lence of smoking (19% vs. 25%) and CVD (3.2% vs.
5.1%) and the proportion of participants assigned to the
intervention measures (36% vs. 41%) were lower among
participants. No significant difference was found
between the two groups with respect to age, systolic and
diastolic blood pressure, FPG, 2 h-PCPG and HDL-C.
The baseline characteristics of the participants by
BMI-MetS categories are presented in Table 1 and 2. In
both sexes, all components of MetS as well as age, his-
tory of CVD and family history of diabetes and educa-
tional status varied significantly by joint BMI-MetS
status. Among 2,189 men, 4.3% were normal weight
with MetS (resembling the normal-weight/MetS pheno-
type), and 29% were overweight or obese without MetS
(resembling the obese/without MetS phenotype). About
38.1% of the participants were normal weight, without
MetS, and 28.8% were overweight or obese with MetS.
Among normal-weight participants, 10.1% had MetS,
and among overweight and obese subjects, 50.1% did
not have MetS. Among women (n = 3,064), 2.3% repre-
sented the normal-weight/MetS phenotype, and 41.7%,
the obese/without MetS phenotype; 28.0% of women
were normal weight, without MetS, and 27.9% were
overweight or obese with MetS. Among normal-weight
women, 7.7% had MetS, and among overweight and
obese subjects, 59.9% did not have MetS.
During follow-up (median 6.5 years), diabetes was
ascertained in 369 of participants (cumulative incidence:
men 6.7% and women 7.2%). Cumulative incidences of
diabetes among normal weight, overweight, and obese
men were 3.5, 7.2 and 14.8%, respectively. The corre-
sponding figures among women were 2.7, 6.2, and
13.4%.
The cumulative incidence of diabetes stratified by
BMI-MetS categories in each sex are shown in the Fig-
ure 2. The cumulative incidence of diabetes were gener-
ally higher among participants with MetS as compared
to those without MetS. In men, the cumulative inci-
dence of diabetes increase with increasing levels of BMI,
regardless of MetS status. In women, among those with-
out MetS the cumulative incidence of diabetes was rela-
tively the same across BMI groups, whereas among
those with MetS the highest incidence was observed in
obese women.
The individual effects of BMI and MetS on diabetes in
both age- and multivariate-adjusted models are
Table 1 Distribution of baseline characteristics of the women across BMI-MetS categories among women
Women Normal weight Normal weight Overweight Overweight Obese Obese
Without MetS With MetS Without MetS With MetS Without MetS With MetS p
(N = 859) (N = 72) (N = 907) (N = 331) (N = 371) (N = 524)
Diabetic, n (%) 14(1.6) 11(15.3) 35(3.9) 42(12.7) 14(3.8) 106(20.2)
Age, y 33.4(10.63) 52.3(11.79
a 39.2(11.20)
a 49.4(11.92)
a 41.2(10.98)
a 48.2(10.84)
a <0.001
BMI, kg.m-2 22.1(2.12) 23.4(1.33)
a 27.3(1.41)
a 27.8(1.38)
a 32.7 (2.69)
a 33.8(3.24)
a <0.001
Waist, cm 74.9(7.63) 82.1(8.08)
a 85.3(6.92)
a 92.4(7.45)
a 95.0 (8.68)
a 102.5(7.90)
a <0.001
SBP, mmHg 107.6(11.70) 131.2(17.44)
a 113.0(13.68)
a 130.9(19.74)
a 116.6 (14.42)
a 129.3(19.64)
a <0.001
DBP, mmHg 71.7(8.36) 82.5(8.34)
a 75.1(8.20)
a 84.5(9.55)
a 78.0 (9.06)
a 84.7(10.14)
a <0.001
FPG, mmol/L 4.75(0.44) 5.30(0.56)
a 4.87(0.45)
a 5.23(0.59)
a 4.82 (0.45) 5.27(0.59)
a <0.001
2hPCPG, mmol/L 5.42(1.26) 6.77(1.58)
a 5.90(1.39)
a 6.92(1.64)
a 5.8 9(1.33)
a 7.00(1.61)
a <0.001
HDL-C, mmol/L 1.24(0.29) 1.09(0.20)
a 1.18(0.29)
a 1.04(0.21)
a 1.24 (0.30) 1.05(0.23)
a <0.001
Triglycerides, mmol/L 1.04(1.01-1.07) 2.31 (2.12-2.51)
a 1.36 (1.32-1.4)
a 2.35(2.25-2.46)
a 1.34 (1.29-1.4)
a 2.32 (2.24-2.41)
a <0.001
Intervention, (%) 301(35.0) 29(40.3) 337(37.2) 123(37.2) 131(35.3) 187(35.7) 0.890
Smoking (%) 29(3.4) 3(4.2) 51(5.6) 15(4.5) 17 (4.6) 30(5.7) 0.273
Hypertension, (%) 36(4.2) 35(48.6)
† 66(7.3)
† 159(48.3)
b 53 (14.3)
b 243(46.6)
b <0.001
History of CVD, (%) 4(0.5) 4(5.6)
b 18(2.0)
b 18(5.4)
b 8 (2.2)
b 26(5.0)
b <0.001
Education, (%) Illiterate 139(16.2) 48(66.7)
b 256(28.2)
b 189(57.1)
b 138 (37.2)
b 327(62.4)
b <0.001
Under diploma 589(68.6) 19(26.4)
b 559(61.6)
b 131(39.6)
b 209 (56.3)
b 183(34.9)
b
Over diploma 131(15.3) 5(6.9) 92(10.1)
b 11(3.3)
b 24 (6.5)
b 14(2.7)
b
Family history DM,(%) 196(22.8) 20(27.8) 261(28.8)
b 91(27.5) 105 (28.3) 170(32.4)
b 0.005
BMI, body mass index; CVD: Cardiovascular disease, DBP, diastolic blood pressure; FPG, fasting plasma glucose, HDL-C: High density lipoprotein cholesterol, MetS,
metabolic syndrome; SBP, systolic blood pressure; 2hPCPG; 2 hours post-challenge plasma glucose,
Data has been represented either as mean (SD) for continuous variables or n(%) for categorically distributed variables ANOVA; % is shown for categorical
variables with P value according to chi-square; TG was log-transformed and is shown as geometric mean (CI).
BMI (kg.m
-2) categories: normal <25; overweight, 25-30; and obese ≥ 30.
Hypertension: Blood pressure ≥ 140/90 and/or taking of antihypertensive medication.
aP < 0.05 compared with normal-weight participants without MetS. (base on Dunnett t-test).
b P < 0.01 compared with normal-weight participants without MetS. (base on chi-square test).
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men, overweight men had an increased risk of diabetes
with an age-adjusted OR of 2.1 (95%CI 1.3-3.0), and
obese men had an even greater OR of 4.7 (95%CI 2.6-
6.8). Among women, the corresponding figures were 2.0
(95%CI 1.2-3.1) and 4.2 (95%CI 2.6-6.7), respectively. As
compared to those without MetS participants who met
the MetS criteria had an increased risk of incident dia-
betes with age-adjusted OR of 3.1 (95%CI 2.2-4.4) and
6.1 (95%CI 4.4-8.5) among men and women, respectively
(Table 3). Adjustment for confounders attenuated the
association with both MetS and BMI; however, the rela-
tionship remained significant among women.
Examination of the combined effect of BMI and MetS
is shown in Table 3. With the exception of the over-
weight men without MetS, each group had a statistically
significant increased multivariate-adjusted risk of dia-
betes compared with the normal-weight individuals
without MetS. When the individuals with and without
MetS within the same BMI strata were compared with
Wald test, multivariate-adjusted OR increased from 1.6
to 3.4 (P = 0.052) for overweight men and from 2.3 to
7.7 (P = 0.001) for overweight women; and from 3.6 to
5.7 (P = 0.370) for 11 obese men and from 2.2 to 12.6
(P<0.0001) for obese women. These increases in risk
were large and particularly significant among women.
However, among those with MetS, when the overweight
Table 2 Distribution of baseline characteristics of the men across BMI-MetS categories among men
Men Normal weight Normal weight Overweight Overweight Obese Obese
Without MetS With MetS (N = 93) Without MetS With MetS Without MetS With MetS p
(N = 830) (N = 552) (N = 400) (N = 81) (N = 230)
Diabetic, (%) 23(2.8) 9(9.7) 26(4.7) 43(10.8) 8(9.9) 38(16.5)
Age, y 41.0(14.64) 49.4(15.64)
a 41.9(12.98) 47.9(13.39)
a 42.0(12.90) 44.8(13.34)
a <0.001
BMI, kg.m-2 22.2(2.00) 23.4(1.39)
a 26.9(1.31)
a 27.6(1.38)
a 31.9(1.84)
a 32.6(2.96)
a <0.001
Waist, cm 78.80(6.66) 84.39(6.49)
a 90.38(5.32)
a 95.06(5.77)
a 101.35(6.90)
a 105.08(7.87)
a <0.001
SBP, mmHg 113.8(14.96) 127.9(16.19)
a 116.4(13.58)
a 129.2(18.34)
a 118.6(16.37)
a 128.9(17.36)
a <0.001
DBP, mmHg 73.1(9.30) 82.3(10.30)
a 76.5 (8.92)
a 83.9(10.55)
a 78.1(8.78)
a 84.9(10.39)
a <0.001
FPG, mmol/L 4.89(0.45) 5.35(0.64)
a 4.96(0.47) 5.27(0.58)
a 4.99(0.35) 5.27(0.55)
a <0.001
2hPCPG, mmol/L 5.19(1.45) 6.33(1.85)
a 5.66(1.59)
a 6.30(1.88)
a 6.11(1.77)
a 6.32(1.85)
a <0.001
HDL-C, mmol/L 1.06(0.24) 0.85(0.15)
a 1.00(0.23
a 0.89(0.18
a 1.09(0.23) 0.89(0.19)
a <0.001
Triglycerides, mmol/L 1.3(1.26-1.35) 2.6 (2.36-2.77)
a 1.7 (1.61-1.75)
a 2.6(2.45-2.68)
a 1.5(1.34-1.68) 2.5 (2.31-2.60)
a <0.001
Intervention, n (%) 285(34.3) 21(22.6) 209(37.9) 141(35.3) 33(40.7) 92(40.0) 0.042
Smoking (%) 362(43.9) 37(39.8) 212(38.4) 161(40.5) 22(27.2)
b 96(41.9) 0.052
Hypertension, n (%) 64(7.7) 36(38.7)
b 57(10.3) 158(39.7)
b 9(11.1) 87(38.2)
b <0.001
History of CVD, n (%) 20(2.4) 8(8.6)
b 18(3.3) 30(7.5)
b 1(1.2) 14(6.1)
b <0.001
Education, n (%) <0.001
Illiterate 167(20.1) 30(32.3)
b 116(21.0) 126(31.5)
b 24(29.6) 68(29.6)
b
Under diploma 496(59.8) 45(48.4) 329(59.6) 204(51.0)
b 48(59.3) 126(54.8)
Over diploma 167(20.1) 18(19.4) 107(19.4) 70(17.5) 9(11.1) 36(15.7)
Family history DM (%) 176(21.2) 18(19.4) 146(26.4) 105(26.3) 21(25.9) 81(35.2)
b 0.001
BMI, body mass index; CVD: Cardiovascular disease, DBP, diastolic blood pressure; FPG, fasting plasma glucose, HDL-C: High density lipoprotein cholesterol, MetS,
metabolic syndrome; SBP, systolic blood pressure; 2hPCPG; 2 hours post-challenge plasma glucose,
Data has been represented either as mean (SD) for continuous variables or n(%) for categorically distributed variables ANOVA; % is shown for categorical
variables with P value according to chi-square; TG was log-transformed and is shown as geometric mean (CI).
BMI (kg.m
-2) categories: normal <25; overweight, 25-30; and obese ≥ 30.
Hypertension: Blood pressure ≥ 140/90 and/or taking of antihypertensive medication.
aP < 0.05 compared with normal-weight participants without MetS. (base on Dunnett t-test).
b P < 0.01 compared with normal-weight participants without MetS. (base on chi-square test).
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Figure 2 The cumulative incidence of diabetes across BMI-
MetS categories. Among men (left) and women (right). MetS,
metabolic syndrome. Normal weight, <25 (kg.m
-2); overweight, 25-
30 (kg.m
-2); and obese, ≥30 (kg.m
-2).
Hadaegh et al. BMC Public Health 2011, 11:383
http://www.biomedcentral.com/1471-2458/11/383
Page 5 of 9and obese groups were compared with the normal-
weight group, modest increases in the ORs were not sta-
tistically significant neither in men nor in women
(P>0.2).
Life style modification intervention measures were not
associated with 6-year risk of incident diabetes. When
we repeated the analyses in participant not assigned to
the lifestyle modification intervention the results
remained essentially unchanged (Table 4). However, to
capture full power (sample size) and information we did
not split the original sample for final presentation.
Discussion
For the first time, we studied the hypothesized sex-spe-
cific heterogeneity in the MetS status of men and
women with normal weight, overweight, or obesity, with
respect to the risk of incident diabetes. Consistent with
previous studies, we demonstrated that BMI and MetS
are significant predictors of diabetes [2,35,36]. This
study further revealed that the magnitude of the associa-
tion with MetS is greater than BMI, when examining the
combined relationship of BMI and MetS. Joint analyses
broaden our understanding of risk factors’ relative influ-
ence on diabetes by showing that individuals with nor-
mal-weight/MetS phenotype had an increased risk of
incident diabetes 3-9 times that of normal weight indivi-
duals without MetS; and that the overweight and obesity
conferred an increased risk of incident diabetes both
among those with and without MetS. Of importance
was our finding that multivariate-adjusted risk of inci-
dent diabetes due to increased BMI began to appear ear-
lier in women than in men.
There is no consensus regarding the definitions of
body size phenotypes, the reported prevalence of the
Table 3 Contribution of individual and combined effects of BMI and MetS to the risk of incident diabetes
Men Women
Age adjusted Multivariable-adjusted
a Age adjusted Multivariable-adjusted
a
OR 95% CIs P OR 95% CIs P OR 95% CIs P OR 95% CIs P
MetS
b 3.1 2.2-4.4 <0.001 2.9 2.1-4.2 <0.001 6.1 4.4-8.5 <0.001 5.8 4.2-8.2 <0.001
BMI (kg.m
-2)
c
<25 1.0 1.0 1.0 1.0
25-30 2.1 1.3-3.2 0.001 1.9 1.3-3.0 0.003 2.0 1.2-3.1 0.005 1.9 1.2-3.1 0.006
≥30 4.7 2.93-7.6 <0.001 4.2 2.6-6.8 <0.001 4.2 2.7-6.7 <0.001 3.9 2.5-6.3 <0.001
No MetS-BMI (kg.m
-2)
d
<25 1.0 1.0 1.0 1.0
25-30 1.7 1.0-3.1 0.063 1.6 0.9-2.9 0.096 2.3 1.2-4.3 0.010 2.3 1.2-4.3 0.012
≥30 3.8 1.7-8.9 0.002 3.6 1.5-8.4 0.003 2.2 1.0-4.7 0.039 2.2 1.0-4.7 0.044
MetS-BMI (kg.m
-2)
<25 3.0 1.3-6.9 0.007 3.1 1.3-7.0 0.007 9.3 3.9-22.1 <0.001 8.8 3.7-21.2 <0.001
25-29.9 3.6 2.1-6.1 <0.001 3.4 2.0-5.8 <0.001 7.7 4.0-14.7 <0.001 7.7 4.0-14.9 <0.001
≥30 6.5 3.8-11.2 <0.001 5.7 3.3-9.9 <0.001 13.5 7.4-24.6 <0.001 12.6 6.9-23.2 <0.001
BMI, body a mass index, calculated as weight (kg) divided by height (m) squared; MetS, metabolic syndrome.
a. OR adjusted for age, family history of diabetes, history of CVD, education, smoking, and intervention
b. Reference: individuals without MetS
c. Reference: normal-weight individuals
d. Reference: normal-weight individuals without MetS
Table 4 Contribution of combined effects of BMI and MetS to the risk of incident diabetes among individuals not
assigned to lifestyle modification intervention measures
Men Women
MetS-BMI states Odds ratio
a (95% CIs) P value Odds ratio
a (95% CIs) P value
No MetS BMI <25 1
b (reference group) - 1
b (reference group) -
BMI 25-30 1.3 (0.7-2.8) 0.415 1.9 (0.9-4.0) 0.115
BMI ≥30 4.1 (1.5-11.0) 0.006 2.6 (1.1-6.1) 0.031
MetS BMI <25 2.6 (1.0-6.7) 0.042 9.0 (3.1-26.0) 0.000
BMI 25-30 2.5 (1.3-4.7) 0.007 6.4 (2.9-14.0) 0.000
BMI ≥30 3.6 (1.8-7.3) 0.000 11.2 (5.4-22.9) 0.000
BMI, body a mass index, calculated as weight (kg) divided by height (m) squared; MetS, metabolic syndrome.
a. OR adjusted for age, family history of diabetes, history of CVD, education, and smoking.
b. Combination status of MetS-BMI was included as a polychotomous variable with 6 categories. Reference group was normal-weight individuals without MetS
Hadaegh et al. BMC Public Health 2011, 11:383
http://www.biomedcentral.com/1471-2458/11/383
Page 6 of 9normal-weight/MetS and obese/without MetS pheno-
types, thus, has been widely ranged 12 [15-18]. In this
population-based study we observed that there were
small numbers of men and women with normal weight
who had MetS, resembling the normal-weight/MetS
phenotype described by Ruderman and others [6-8] and
modest numbers with obesity but without MetS, resem-
bling the obese/without MetS phenotype described by
Brochu, Karelis, and others [12-14,37]. The prevalence
of the normal-weight/MetS and obese/without MetS
phenotype in this study was 3.1% and 40.2%, respec-
tively. The corresponding prevalence reported to be
8.6% and 65.8% among US adults [19], and 8.7% and
15.2% [18] among Korean adults.
The present findings indicate that normal-weight/
MetS phenotype confers increased risk of incident dia-
betes, highlighting the importance of MetS among nor-
mal weight individuals. Contrariwise, overweight and
obesity puts metabolically healthy individuals at not
much so increased risk for developing diabetic. The
magnitude of the association with diabetes risk for MetS
was higher than that of obesity. These findings under-
score the critical importance of MetS as a determinant
of diabetes.
The presence of MetS augmented risk for incident
diabetes, regardless of obesity status, therefore, screening
in normal or slightly elevated BMI can help preventing
diabetes [5]. Karelis et al [38] hypothesized and Meigs et
al [10] showed that the normal-weight/MetS or obese/
without MetS phenotypes exist in the community and
have differential associations with diabetes. In line with
previous studies[19], we observed that the normal-
weight/MetS phenotype was associated with 3 and 9
fold risk factor adjusted OR for diabetes in men and
women, respectively; accounting, respectively, for 5% to
6% of incident cases in this population. As expected, the
highest diabetes incident rate (62%) was observed
among overweight and obese individuals with MetS.
Our results varied, however, from previous studies [19]
in that we observed an increased risk of diabetes asso-
ciated with obese/without MetS phenotype accounting
for 22% of incident cases in this population.
Meigs et al cautioned the interpretation that indivi-
duals with obese/without MetS phenotype are really
obese and healthy [10]. Data from Sweden refuted the
notion that obese/without MetS phenotype is a benign
condition [39]. In the interim, we could not confirm the
existence of a healthy obese phenotype based on the
a b s e n c eo fM e t S .T h eT L G Sp a r t i c i p a n t sw i t ho b e s e /
without MetS phenotype were younger than their obese
counterparts with MetS, it is still possible that the sus-
ceptible person has not yet developed the MetS; risk fac-
tor may begin to cluster in this subgroup as they age
putting them at an increased risk for diabetes [10].
Trends in lipid profile have previously been documented
to be more favorable among obese participants of the
TLGS than among their overweight or normal weight
counterparts [40]. The favorable trends in metabolic
markers, however, may be annihilated by unfavorable
trends in obesity [41]. This means that some of the
overweight/obese participants without MetS at baseline
might have developed MetS during follow-up, which in
turn led to incident diabetes. This finding underscores
the need for follow up for timely detection of deviation
from normal metabolic state in this sub-groups [11].
More stringent definition rather than absence of MetS,
need to be considered since the goal is to define true
obese/without MetS population which is different from
a non-MetS population [11,14].
The major strength of our sex-specific prospective
study lies in the reliable follow up in a well-character-
ized population-based sample in which diabetes and its
risk factors have been assessed with standardized mea-
sures both at baseline and follow up, systematically
recording all of the variables required to the define
MetS and completeness of ascertainment and accuracy
of classification.
The interpretation of present data needs to be assessed
within the context of the potential limitation of our
study. First, the modest numbers of diabetic patients dur-
ing 6.5 years follow up, might lead to inexact estimates
for overweight men without MetS in sex stratified analy-
sis adjusted for diabetic risk factors, no firm conclusions,
therefore, should be drawn regarding this non significant
association. Second, some misclassification of diabetes
status may have occurred due to lacking confirmatory
test for newly diagnosed diabetes. Third, there is an
innate limitation to the concept of MetS, which has dif-
ferent definitions. We, however, have chosen among dif-
ferent definitions, the one that has been agreed upon by
developers of different definitions of MetS [26]. Finally, it
must be emphasized that the results of this study were
determined in an Iranian urban adult population and
further studies should be conducted to determine
whether our findings are applicable to other populations.
Conclusions
The results of this study establish that there is heterogene-
ity in BMI-metabolic risk sub-phenotypes in the popula-
tion and that the MetS is a critical factor that confers risk
for diabetes. Our finding highlights the importance of
screening for MetS even in normal weight individuals,
which is a laudable approach from a health education as
well as a public health point of view and relates to the pre-
vention of diabetes. In the presence of the MetS, increas-
ing levels of BMI no longer contributed to the risk of
incident diabetes. Furthermore, in participants without
MetS, obesity increased risk for incident diabetes. Thus, in
Hadaegh et al. BMC Public Health 2011, 11:383
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Page 7 of 9every day encounter as well as public health setting weight
reduction measures, should be encouraged in conjunction
with achieving metabolic targets not addressed by current
definition of MetS.
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